| |
|
TPG Capital |
|
TPG Capital has announced that it has entered into a definitive agreement to acquire Quebec based Axcan Pharma Inc. in an all cash deal valued at US$1.3 billion. Details |
|
11/27/2007/2007 |
|
| |
|
Cryocath Technologies Inc. |
|
CryoCath Technologies Inc. has announced an agreement to sell their surgical portfolio to ATS Medical in a $22 million cash transaction. Davies is representing CryoCath Technologies Inc. Details |
|
7/11/2007/2007 |
|
| |
|
MethylGene Inc. |
|
MethylGene Inc., a biopharmaceutical company seeking treatment for cancer and infectious diseases, completed a bought deal financing with an underwriting syndicate led by Canaccord Capital Corporation Details |
|
3/2/2007/2007 |
|
| |
|
MethylGene Inc. |
|
MethylGene Inc. entered into a Collaborative Research, Development and Commercialization Agreement for its histone deacetylase (HDAC) inhibitors with Pharmion Corporation in North America, Europe, the Middle East and certain other markets. Details |
|
8/30/2006/2006 |
|
| |
|
Innodia Inc. |
|
Represented the venture capitalist investors in a $10 million convertible debenture offering of Innodia Inc. Details |
|
3/31/2006/2006 |
|
| |
|
Adaltis Inc. |
|
Adaltis Inc. completed a $15 million unsecured convertible debenture financing. Details |
|
3/27/2006/2006 |
|
| |
|
Decision Resources, Inc. |
|
Acted for Decision Resources, Inc., one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare industry insight and analysis, in its acquisition of Millennium Research Group Inc. Details |
|
2/2/2006/2006 |
|
| |
|
MethylGene Inc. |
|
MethylGene Inc. entered into of a Collaborative Research, Development and Commercialization Agreement for its histone deacetylase (HDAC) inhibitors with Pharmion Corporation in North America, Europe, the Middle East and certain other markets. Details |
|
1/30/2006/2006 |
|
| |
|
Patheon Inc. |
|
Davies acted for Patheon Inc., a leading independent provider of pharmaceutical manufacturing and development services, in its new North American credit facilities in the amount of US$290 million Details |
|
12/15/2005/2005 |
|
| |
|
Genus |
|
Davies represented Genus, the world’s leading Bovine Genetics company, in Canada in the financing of its all cash acquisition of 63.2% of Sygen International valued at GBP 187 million. Details |
|
10/31/2005/2005 |
|
| |
|
Gemin X Biotechnologies Inc. |
|
Gemin X Biotechnologies Inc. completed a US$65.2 million financing ..... Details |
|
5/26/2005/2005 |
|
| |
|
PainCeptor Pharma Corporation |
|
PainCeptor Pharma Corporation, a new leading-edge biopharmaceutical company focused on novel and effective therapeutic drugs for the treatment of acute and chronic pain, successfully completed a Cdn$23 million initial private placement. Details |
|
12/1/2004/2004 |
|
| |
|
MethylGene Inc. |
|
MethylGene Inc., a biopharmaceutical company seeking treatment for cancer and infectious diseases, completed its initial public offering for gross proceeds of $ 21,632,500. Details |
|
7/29/2004/2004 |
|
| |
|
CML Healthcare Inc. |
|
CML Healthcare Inc. completed a plan of arrangement valued at $1.25 Billion. Details |
|
3/20/2004/2004 |
|
| |
|
Neurochem Inc. |
|
Public offering in the U.S. and Canada of $62 million of common shares of Neurochem Inc. Details |
|
3/20/2003/2003 |
|
| |
|
CryoCath Technologies Inc. |
|
Purchase by CryoCath Technologies Inc. of Endocare, Inc.'s cardiac-related product manufacturing operations and related intellectual property. Details |
|
3/20/2003/2003 |
|
| |
|
RBC Dominion Securities and syndicate |
|
Private placement of $200 million of debentures by Concordia University. Details |
|
3/20/2002/2002 |
|
